Although these biomarkers will be utilised initially for exploratory purposes, they are important for understanding how patients respond to therapies targeting tau pathology and for enhancing our understanding of the pathophysiological features of AD in relation to the pathophysiology of tau protein in AD. Here, MAPT is linked to Alzheimer disease.